Next Article in Journal
Flavivirus Entry Receptors: An Update
Next Article in Special Issue
Gene Therapy Strategies to Exploit TRIM Derived Restriction Factors against HIV-1
Previous Article in Journal
Replication Cycle and Molecular Biology of the West Nile Virus
Previous Article in Special Issue
Stem-Cell-Based Gene Therapy for HIV Infection
Article Menu

Export Article

Open AccessArticle
Viruses 2014, 6(1), 54-68;

CCR5 as a Natural and Modulated Target for Inhibition of HIV

Calimmune, Inc., Los Angeles, California, CA 90024, USA
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany
Cellex GmbH, 01307 Dresden, Germany
Author to whom correspondence should be addressed.
Received: 2 September 2013 / Revised: 2 December 2013 / Accepted: 11 December 2013 / Published: 30 December 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
Full-Text   |   PDF [286 KB, uploaded 12 May 2015]   |  


Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor, predominantly the chemokine receptor CCR5. CCR5-delta32 homozygosity results in a truncated protein providing natural protection against HIV infection—this without detrimental effects to the host—and transplantation of CCR5-delta32 stem cells in a patient with HIV (“Berlin patient”) achieved viral eradication. As a more feasible approach gene-modification strategies are being developed to engineer cellular resistance to HIV using autologous cells. We have developed a dual therapeutic anti-HIV lentiviral vector (LVsh5/C46) that down-regulates CCR5 and inhibits HIV-1 fusion via cell surface expression of the gp41-derived peptide, C46. This construct, effective against multiple strains of both R5- and X4-tropic HIV-1, is being tested in Phase I/II trials by engineering HIV-resistant hematopoietic cells. View Full-Text
Keywords: CCR5; C46; gene therapy; HIV; stem cell transplantation CCR5; C46; gene therapy; HIV; stem cell transplantation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Burke, B.P.; Boyd, M.P.; Impey, H.; Breton, L.R.; Bartlett, J.S.; Symonds, G.P.; Hütter, G. CCR5 as a Natural and Modulated Target for Inhibition of HIV. Viruses 2014, 6, 54-68.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top